1. Home
  2. WVE vs DRUG Comparison

WVE vs DRUG Comparison

Compare WVE & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

N/A

Current Price

$3.88

Market Cap

744.8M

Sector

Health Care

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

N/A

Current Price

$49.21

Market Cap

778.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WVE
DRUG
Founded
2012
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
744.8M
778.4M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
WVE
DRUG
Price
$3.88
$49.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
18
8
Target Price
$18.53
★ $166.78
AVG Volume (30 Days)
★ 2.8M
68.0K
Earning Date
11-09-2026
08-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $3,704,000.00
N/A
Revenue This Year
$20.53
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 149.43
N/A
52 Week Low
$3.56
$48.94
52 Week High
$21.73
$123.75

Technical Indicators

Market Signals
Indicator
WVE
DRUG
Relative Strength Index (RSI) 36.57 26.75
Support Level N/A N/A
Resistance Level $6.33 $78.35
Average True Range (ATR) 0.21 2.85
MACD -0.02 -0.69
Stochastic Oscillator 38.99 14.04

Price Performance

Historical Comparison
WVE
DRUG

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: